Tela Bio Earnings Call Balances Momentum and Risk

Tela Bio, Inc. ((TELA)) has held its Q1 earnings call. Read on for the main highlights of the call.

Tela Bio, Inc. struck a cautiously optimistic tone on its latest earnings call, pairing modest top-line growth with signs of building commercial momentum. Management highlighted a fully staffed U.S. sales force, a major new product launch, strong international expansion and robust unit growth, while acknowledging margin pressure, a wider net loss and execution risks that must be managed to unlock a stronger second half.

Revenue Trends and Updated Guidance Context

Tela Bio reported Q1 2026 revenue of $19.1 million, a 3% year-over-year increase from $18.5 million that underscores early commercialization headwinds despite multiple growth drivers. Management nevertheless reiterated full-year guidance for at least 8% revenue growth over 2025 and set Q2 revenue expectations at roughly $20 million, signaling confidence in a back-half ramp as new reps mature.

International Surge Led by European Hernia Business

International revenue reached $3.7 million, up 41% from the prior year and driven entirely by the hernia portfolio, making ex-U.S. markets a clear standout. The U.K. National Health Service selected OviTex for complex abdominal procedures under value-based procurement, and management argued these cost and clinical advantages should translate across other European health systems.

OviTex Portfolio: Strong Unit Growth but Softer Pricing

OviTex revenue edged up to $12.6 million from $12.1 million, but unit volumes jumped 16% to 5,800 implants versus 5,000 a year ago, reflecting deepening procedural penetration. The company said its broad portfolio allows it to participate in open, laparoscopic and robotic trends, though a shift toward smaller-sized products pressured average selling prices and muted dollar growth.

Launch of OviTex LTR Fully Resorbable Platform

On April 1, Tela Bio executed the full U.S. commercial launch of OviTex LTR, a fully resorbable tissue-based hernia solution positioned as one of the few offerings of its kind. Management reported overwhelmingly positive early field feedback and noted that pricing was set comparable to existing products to maintain the brand’s value proposition for hospitals and payers.

Scaled U.S. Commercial Footprint Poised for Ramp

The U.S. commercial organization is now fully staffed at 2026 target levels, giving Tela Bio the largest field team in its history and over 90 territory managers. Roughly 40% of the sales force was hired between Q4 and Q1, and a significant portion of those reps is expected to reach a six-month productivity inflection by late Q2, underpinning expectations for improved sales momentum in the second half.

LiquiFix and Adjacent Products Extend Reach

LiquiFix continued to build traction as a complementary product line, delivering more than 50% year-over-year growth and helping Tela Bio open doors with new surgeons. Management framed LiquiFix as a strategic wedge that deepens account penetration, broadens the procedural footprint and supports cross-selling of the broader OviTex portfolio over time.

Clinical Evidence Strengthens Competitive Positioning

New data featured in a meta-analysis presented at SAGES, along with additional published studies, indicated that OviTex is safe and effective with significantly lower recurrence rates versus rival offerings. The company stressed that influential academic authors and real-world datasets are reinforcing its clinical and economic value story, which could support broader adoption and contracting leverage.

Board Refresh Adds Scaling and Med-Tech Expertise

Tela Bio announced a board refresh that brings in four new directors with deep experience in medical technology and commercial scaling. Management framed these changes as a way to strengthen strategic oversight and governance as the company moves from early adoption into a more mature commercial phase and works toward a path to profitability.

Gross Profit Holds Despite Margin Pressure

Gross profit in Q1 2026 was $12.5 million, essentially flat year over year and suggesting a relatively resilient cost structure. However, gross margin slipped to 66% from 68% as higher charges for excess and obsolete inventory weighed on profitability, reflecting the growing complexity of managing a broader product lineup.

Sluggish Top-Line Growth Highlights Near-Term Friction

The 3% revenue growth in Q1 stands in contrast to the scale of Tela Bio’s strategic investments, including a fully built-out sales organization and a broadened product suite. Management acknowledged that contract timing, territory realignments and rep maturation are creating near-term friction, making a stronger second half crucial to achieving the full-year growth target.

Net Loss, Operating Costs and Interest Expense

The company posted a net loss of $12.3 million in Q1, wider than the $11.3 million loss a year ago, as interest expense rose to $2.1 million following a larger credit facility put in place in late 2025. Operating loss remained elevated at $10.5 million, with total operating expenses of $23.0 million and limited operating leverage visible in the quarter as Tela Bio invests heavily in commercial expansion.

PRS Utilization Volatility and Concentration Risk

OviTex PRS revenue dipped slightly to $5.9 million from $6.0 million even as the broader portfolio grew, as utilization was hit by the temporary absence of several high-volume implanters due to maternity leave, vacations and oral boards. Management highlighted this as evidence of concentration risk in a small number of high-ASP users, underscoring the importance of further broadening the surgeon base.

Product Mix and ASP Compression Dynamics

While OviTex unit growth was robust, a higher mix of smaller-sized implants compressed average selling prices and limited revenue expansion. This product mix shift illustrates how procedural patterns and case types can impact pricing power, and it reinforces the company’s focus on growing overall case volume and higher-value indications to drive sales.

Balance Sheet and Need for Commercial Execution

Tela Bio ended the quarter with $39.5 million in cash and cash equivalents, which management did not characterize as an immediate concern but sits against ongoing operating losses and rising interest costs. The combination increases the strategic importance of delivering the planned sales ramp, realizing productivity from the expanded sales force and moving closer to sustainable cash generation.

Forward-Looking Outlook and Execution Milestones

Management reaffirmed its outlook for at least 8% revenue growth in 2026 and guided to roughly $20 million of revenue in Q2, with international strength, OviTex unit growth and LiquiFix momentum as key pillars. The company emphasized that the commercial launch of OviTex LTR, maturation of recently hired sales reps, and timely execution of contracts and territory realignments are the central variables that will determine whether the anticipated second-half inflection materializes.

Tela Bio’s earnings call painted a picture of a company moving from validation to scale, with strong clinical data, a richer product portfolio and a larger sales force supporting a constructive long-term narrative. Investors, however, will be watching closely to see if management can translate these ingredients into faster revenue growth, improved margins and a path toward profitability as 2026 progresses.